Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amrubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 4/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | ECE1 | P42892 | 1/20 | 0.58 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 9/20 | 0.57 |
| ▸ | THRB | P10828 | 9/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.57 |
| ▸ | BLM | P54132 | 8/20 | 0.57 |
| ▸ | RECQL | P46063 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.57 |
| ▸ | S100A4 | P26447 | 6/20 | 0.57 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | USP2 | O75604 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amrubicin SCHEMBL2524979 | 1.00 | CHRM1 (0.98) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL6254801 | 0.99 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL13091911 | 0.99 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL10061868 | 0.99 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL868435 | 0.99 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL10080133 | 0.99 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL10079225 | 0.99 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL9140 | 0.99 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL119022 | 0.99 | CHRM1 (1.00) | CHRM1TBXA2RPTGS1ADRA1AECE1 | |
| Amrubicin SCHEMBL23909356 | 0.96 | CHRM1 (0.95) | CHRM1TBXA2RPTGS1ADRA1AECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 832 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638443-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | claimed |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES INC (US) | 2025-03-13 | — | — | US | claimed |
| WO-2024130344-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | claimed |
| CN-117100701-A | Application of ginsenoside liposome in immune regulation | 复旦大学附属华山医院 | 2023-11-24 | — | — | CN | claimed |
| CN-116407503-A | Blank liposome composition with pentacyclic triterpene compound as membrane material, and preparation method and application thereof | 复旦大学 | 2023-07-11 | — | — | CN | claimed |
| EP-4135686-A1 | BASIC CHEMOTHERAPEUTIC INTRATUMOUR INJECTION FORMULATION | US Nano Food & Drug Inc (US) | 2023-02-22 | — | — | EP | claimed |
| CN-111228219-B | Blank liposome taking ginsenoside Rg3 or analogue thereof as membrane material, preparation method and application thereof | 上海参素药物技术有限公司 | 2023-01-06 | — | — | CN | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| CN-114929213-A | Alkaline chemotherapeutic intratumoral injection composition | 美国纳米食品药品公司 | 2022-08-19 | — | — | CN | claimed |
| WO-2021211294-A1 | BASIC CHEMOTHERAPEUTIC INTRATUMOUR INJECTION FORMULATION | US Nano Food & Drug INC (US) | 2021-10-21 | — | — | WO | claimed |
| US-20040249137-A1 | Stabilization of amrubicin hydrochloride | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1439185-A1 | STABILIZATION OF AMRUBICIN HYDROCHLORIDE | Sumitomo Chemical Company, Limited (JP) | 2004-07-21 | — | — | EP | claimed |
| EP-1423126-A2 | TREATMENT OF HYPERPROLIFERATIVE CONDITIONS OF BODY SURFACES | Valderm APS (DK) | 2004-06-02 | — | — | EP | claimed |
| CN-1489469-A | Medicine for lung cnncer | ס����ҩ��ʽ���� | 2004-04-14 | — | — | CN | claimed |
| US-20040038913-A1 | Remedies for lung cancer | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-02-26 | — | — | US | claimed |
| EP-1364652-A1 | REMEDIES FOR LUNG CANCER | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-11-26 | — | — | EP | claimed |
| WO-2003015759-A2 | TREATMENT OF HYPERPROLIFERATIVE CONDITIONS OF BODY SURFACES | VALDERM APS (DK) | 2003-02-27 | — | — | WO | claimed |
| US-6376469-B1 | EXCELLENT THERMAL STABILITY AND IS USED IN PRODUCTION OF FREEZE-DRIED FORMULATIONS; CANCER CHEMOTHERAPEUTICAL AGENT | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-04-23 | — | — | US | claimed |
| EP-1034181-A2 | CRYSTALLINE AMRUBICIN HYDROCHLORIDE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | claimed |
| WO-1999028331-A2 | CRYSTALLINE AMRUBICIN HYDROCHLORIDE | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1999-06-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | TOP2A 1002/4885CHRM1 2154/4885TBXA2R 1919/4885 |
| US-20040038913-A1 | Remedies for lung cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MUC1, CD44 | TOP2A 26/4885CHRM1 3971/4885TBXA2R 3136/4885 |
| US-20040249137-A1 | Stabilization of amrubicin hydrochloride | TOP2A, HNRNPH3, SMCHD1 | TOP2A 1/4885CHRM1 4505/4885TBXA2R 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.